NGcGM3 Ganglioside: A Privileged Target for Cancer Vaccines
Active specific immunotherapy is a promising field in cancer research. N-glycolyl (NGc) gangliosides, and particularly NGcGM3, have received attention as a privileged target for cancer therapy. Many clinical trials have been performed with the anti-NGc-containing gangliosides anti-idiotype monoclona...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2010-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2010/814397 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832548695238770688 |
|---|---|
| author | Luis E. Fernandez Mariano R. Gabri Marcelo D. Guthmann Roberto E. Gomez Silvia Gold Leonardo Fainboim Daniel E. Gomez Daniel F. Alonso |
| author_facet | Luis E. Fernandez Mariano R. Gabri Marcelo D. Guthmann Roberto E. Gomez Silvia Gold Leonardo Fainboim Daniel E. Gomez Daniel F. Alonso |
| author_sort | Luis E. Fernandez |
| collection | DOAJ |
| description | Active specific immunotherapy is a promising field in cancer research. N-glycolyl (NGc) gangliosides, and particularly NGcGM3, have received attention as a privileged target for cancer therapy. Many clinical trials have been performed with the anti-NGc-containing gangliosides anti-idiotype monoclonal antibody racotumomab (formerly known as 1E10) and the conjugated NGcGM3/VSSP vaccine for immunotherapy of melanoma, breast, and lung cancer. The present paper examines the role of NGc-gangliosides in tumor biology as well as the available preclinical and clinical data on these vaccine products. A brief discussion on the relevance of prioritization of cancer antigens in vaccine development is also included. |
| format | Article |
| id | doaj-art-b3127abec810436d86ce18398d85e757 |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2010-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-b3127abec810436d86ce18398d85e7572025-02-03T06:13:16ZengWileyClinical and Developmental Immunology1740-25221740-25302010-01-01201010.1155/2010/814397814397NGcGM3 Ganglioside: A Privileged Target for Cancer VaccinesLuis E. Fernandez0Mariano R. Gabri1Marcelo D. Guthmann2Roberto E. Gomez3Silvia Gold4Leonardo Fainboim5Daniel E. Gomez6Daniel F. Alonso7Vaccine Department, Center of Molecular Immunology, Havana 11600, CubaLaboratory of Molecular Oncology, Quilmes National University, Roque Saenz Peña 352, Bernal B1876BXD Buenos Aires, ArgentinaElea Laboratories, C1417AZE Buenos Aires, ArgentinaElea Laboratories, C1417AZE Buenos Aires, ArgentinaChemo-Romikin, C1061ABC Buenos Aires, ArgentinaDivision of Immunogenetics, José de San Martín Clinics Hospital, University of Buenos Aires, C1120AAF Buenos Aires, ArgentinaLaboratory of Molecular Oncology, Quilmes National University, Roque Saenz Peña 352, Bernal B1876BXD Buenos Aires, ArgentinaLaboratory of Molecular Oncology, Quilmes National University, Roque Saenz Peña 352, Bernal B1876BXD Buenos Aires, ArgentinaActive specific immunotherapy is a promising field in cancer research. N-glycolyl (NGc) gangliosides, and particularly NGcGM3, have received attention as a privileged target for cancer therapy. Many clinical trials have been performed with the anti-NGc-containing gangliosides anti-idiotype monoclonal antibody racotumomab (formerly known as 1E10) and the conjugated NGcGM3/VSSP vaccine for immunotherapy of melanoma, breast, and lung cancer. The present paper examines the role of NGc-gangliosides in tumor biology as well as the available preclinical and clinical data on these vaccine products. A brief discussion on the relevance of prioritization of cancer antigens in vaccine development is also included.http://dx.doi.org/10.1155/2010/814397 |
| spellingShingle | Luis E. Fernandez Mariano R. Gabri Marcelo D. Guthmann Roberto E. Gomez Silvia Gold Leonardo Fainboim Daniel E. Gomez Daniel F. Alonso NGcGM3 Ganglioside: A Privileged Target for Cancer Vaccines Clinical and Developmental Immunology |
| title | NGcGM3 Ganglioside: A Privileged Target for Cancer Vaccines |
| title_full | NGcGM3 Ganglioside: A Privileged Target for Cancer Vaccines |
| title_fullStr | NGcGM3 Ganglioside: A Privileged Target for Cancer Vaccines |
| title_full_unstemmed | NGcGM3 Ganglioside: A Privileged Target for Cancer Vaccines |
| title_short | NGcGM3 Ganglioside: A Privileged Target for Cancer Vaccines |
| title_sort | ngcgm3 ganglioside a privileged target for cancer vaccines |
| url | http://dx.doi.org/10.1155/2010/814397 |
| work_keys_str_mv | AT luisefernandez ngcgm3gangliosideaprivilegedtargetforcancervaccines AT marianorgabri ngcgm3gangliosideaprivilegedtargetforcancervaccines AT marcelodguthmann ngcgm3gangliosideaprivilegedtargetforcancervaccines AT robertoegomez ngcgm3gangliosideaprivilegedtargetforcancervaccines AT silviagold ngcgm3gangliosideaprivilegedtargetforcancervaccines AT leonardofainboim ngcgm3gangliosideaprivilegedtargetforcancervaccines AT danielegomez ngcgm3gangliosideaprivilegedtargetforcancervaccines AT danielfalonso ngcgm3gangliosideaprivilegedtargetforcancervaccines |